★ Biotechnology is revolutionizing the early detection of prostate cancer, the incidence of which could increase by 35% in the coming years.

He prostate cancer This is most common among men worldwide: Every eighth man suffers from it during his lifetime. When SpainProstate cancer ranks first first position among the most frequently diagnosed cancers among men. According to the report “Cancer figures in Spain”prepared by the Spanish Society of Medical Oncology (SEOM), during 2024 they will be diagnosed in our country. more 30,300 new cases of prostate cancer.

Prostate cancer is rare in men under 40, but the likelihood of developing prostate cancer increases rapidly after age 40. 50 years. About six out of 10 cases of prostate cancer are found in men over 65 years old. Projections show that there may be an increase of up to 35% men diagnosed with prostate cancer in the next 10-15 years due to the aging population.

He prostate cancer reasons in our country around 6000 deaths annuallyAlthough survival rate has improved significantly in recent years thanks to early detection. In this sense biotechnology It is essential for the diagnosis, treatment and monitoring of prostate cancer and plays a broad role across the entire spectrum of patient care, which we review today on the occasion World Prostate Cancer Day which is celebrated on June 11 thanks to the work of two of our partners: Lifespan And Kibim.

ProstAV® allows you to stratify the risk of developing prostate cancer

Life length is a Spanish biotechnology company, a world leader in telomere measurement and related tests, and has developed and owned an exclusive and patented high-performance technology called TAT® (Telomere Analysis Technology®).

telomere measurement technology life expectancy, SL represents a useful novelty in the diagnosis of prostate cancer has been demonstrated and may also be useful in other types of cancer to provide adequate prevention and health promotion.

“When we talk about prostate cancer, early detection is critical. To make this easier, we have developed a non-invasive test called ProstAV®, “This helps identify the likelihood of prostate cancer, avoiding the need for procedures such as biopsies,” explains the biotech company.

ProstTAV® This is a new dedicated diagnostic tool included in the NHS Portfolio of Shared Services (SNS). An in vitro diagnostic medical device that uses an advanced algorithm to analyze prostate cancer risk. This method is based on the relationship between certain genetic markersknown as telomere profilesand the likelihood of significant prostate cancer, especially in patients with PSA levels between 3 and 10 ng/mL. This test offers three types of results:

· ProsTAV Score: A score that indicates overall risk.

· Gleason probability ≥ 7: assessing the risk of developing moderately aggressive prostate cancer.

· Gleason probability ≥ 8: assessing the risk of developing highly aggressive prostate cancer.

“If the ProsTAV® result is greater than 10%, the physician may decide to perform a confirmatory biopsy. WITH This allows for more adequate identification of patients who actually require a biopsy. and, importantly, discriminate very strictly against those patients who do not require a biopsy, given their low risk of PCa. This reduces the number of unnecessary biopsies by a third and therefore reduces direct healthcare costs. ProsTAV® makes the procedure easier, faster and more comfortable for patients,” they conclude.

QP-Prostate, an artificial intelligence solution for early detection of prostate cancer

Biotechnology is critical in the diagnosis, treatment and monitoring of prostate cancer. Because the image processing improvements and help artificial intelligence when prostate cancer lesions are detected before new types of imaging techniques for identifying cancer cells and its distribution, passing through its role in development of new treatment methods. Biotechnology plays a broad role across the spectrum of treatment for patients with prostate cancer. An area where Quibim excels, developing and creating innovative tools that unlock imaging data to maximize drug delivery programs and improve patient quality of life.

“At Quibim we have developed QP-Prostatean AI-based solution for early detection of prostate cancer, which has benefited more than 5,000 patients across the various medical centers where it has been installed since its launch in December 2023,” they detail.

“By automatically assessing image quality, segmenting the prostate and identifying suspicious lesions thanks to an artificial intelligence model trained on thousands of prostate biopsy and MRI data.QP-Prostate allows radiologists to make more accurate and efficient diagnoses., which helps improve patient care. In the near future, the tool will also include predictive and predictive tools in addition to detecting complex anatomical regions such as neurovascular bundles,” they conclude.

Fountain: Acebio